Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MSCs in Rheumatoid Arthritis
NCT03186417Phase 1Terminated
- Sponsor
- MetroHealth Medical Center
- Start
- Dec 2017
- Primary completion
- Apr 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MSV alogénicas in rheumatoid arthritis (RA) (3 cohorts), sponsored by MetroHealth Medical Center. Primary endpoints: Dose Limiting Toxicity at 14 days, Dose Limiting Toxicity (Acute) at 48 hours and 2 more. Started Dec 2017; status: terminated.
02
Drugs
MSV alogénicas
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03186417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186417.